These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1336948)

  • 1. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of lomefloxacin in patients with cirrhosis.
    Lebrec D; Gaudin C; Benhamou JP
    Am J Med; 1992 Apr; 92(4A):41S-44S. PubMed ID: 1316069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ranitidine on renal clearance of lomefloxacin.
    Sudoh T; Fujimura A; Harada K; Sunaga K; Ohmori M; Sakamoto K
    Eur J Clin Pharmacol; 1996; 51(1):95-8. PubMed ID: 8880059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
    Stone JW; Andrews JM; Ashby JP; Griggs D; Wise R
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1508-10. PubMed ID: 3190181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Leroy A; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1990 Jan; 34(1):17-20. PubMed ID: 2327756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.
    Cowling P; Rogers S; McMullin CM; White LO; Lovering AM; MacGowan AP; Reeves DS
    J Antimicrob Chemother; 1991 Jul; 28(1):101-7. PubMed ID: 1663107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.
    Morrison PJ; Mant TG; Norman GT; Robinson J; Kunka RL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1503-7. PubMed ID: 3214495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.
    Cogo R; Rimoldi R; Mattina R; Imbimbo BP
    Ther Drug Monit; 1992 Feb; 14(1):36-41. PubMed ID: 1312263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraprostatic distribution of lomefloxacin following multiple-dose administration.
    Kovarik JM; de Hond JA; Hoepelman IM; Boon T; Verhoef J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2398-401. PubMed ID: 2088193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.
    Gros I; Carbon C
    Antimicrob Agents Chemother; 1990 Jan; 34(1):150-2. PubMed ID: 2327750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of interaction between lomefloxacin and caffeine in normal volunteers.
    Healy DP; Schoenle JR; Stotka J; Polk RE
    Antimicrob Agents Chemother; 1991 Apr; 35(4):660-4. PubMed ID: 2069371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.
    Kavi J; Stone J; Andrews JM; Ashby JP; Wise R
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):168-70. PubMed ID: 2498102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
    Mant TG
    Am J Med; 1992 Apr; 92(4A):26S-32S. PubMed ID: 1316066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrations of oral lomefloxacin in serum and bronchial mucosa.
    Baldwin DR; Honeybourne D; Andrews JM; Ashby JP; Wise R
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1017-9. PubMed ID: 2393260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.